P552-02 mesylate | CAS#587879-54-7 | sodium channel blocker

MedKoo Cat#: 556070 | Name: P552-02 mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PS 552-02 , also known as P552-02, KM-003, or 552-02, is a sodium channel blocker potentially for the treatment of cystic fibrosis.

Chemical Structure

P552-02 mesylate

CAS#587879-54-7 (mesylate)

Theoretical Analysis

MedKoo Cat#: 556070

Name: P552-02 mesylate

CAS#: 587879-54-7 (mesylate)

Chemical Formula: C20H30ClN7O7S

Exact Mass: 451.1735

Molecular Weight: 548.01

Elemental Analysis: C, 43.83; H, 5.52; Cl, 6.47; N, 17.89; O, 20.44; S, 5.85

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

587879-32-1 (free base) 587879-54-7 (mesylate) 587879-57-0 (HCl)

Synonym

P552-02 mesylate; P552-02; P-552-02; P 552-02; P55202; P-55202; P 55202; PS552-02; PS-552-02; PS 552-02; KM-003; KM 003; KM003;

IUPAC/Chemical Name

3,5-diamino-6-chloro-N-(N-(4-(4-(2,3-dihydroxypropoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide mesylate

InChi Key

ZYOATBKPEFZNGP-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H26ClN7O4.CH4O3S/c20-15-17(22)26-16(21)14(25-15)18(30)27-19(23)24-8-2-1-3-11-4-6-13(7-5-11)31-10-12(29)9-28;1-5(2,3)4/h4-7,12,28-29H,1-3,8-10H2,(H4,21,22,26)(H3,23,24,27,30);1H3,(H,2,3,4)

SMILES Code

O=C(C1=NC(Cl)=C(N)N=C1N)NC(NCCCCC2=CC=C(OCC(O)CO)C=C2)=N.OS(=O)(C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 548.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Coote KJ, Paisley D, Czarnecki S, Tweed M, Watson H, Young A, Sugar R, Vyas M, Smith NJ, Baettig U, Groot-Kormelink PJ, Gosling M, Lock R, Ethell B, Williams G, Schumacher A, Harris J, Abraham WM, Sabater J, Poll CT, Faller T, Collingwood SP, Danahay H. NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia. Br J Pharmacol. 2015 Jun;172(11):2814-26. doi: 10.1111/bph.13075. Epub 2015 Apr 23. PMID: 25573195; PMCID: PMC4439877. 2: Blé FX, Cannet C, Collingwood S, Danahay H, Beckmann N. ENaC-mediated effects assessed by MRI in a rat model of hypertonic saline-induced lung hydration. Br J Pharmacol. 2010 Jun;160(4):1008-15. doi: 10.1111/j.1476-5381.2010.00747.x. PMID: 20590595; PMCID: PMC2936005. 3: Hirsh AJ, Molino BF, Zhang J, Astakhova N, Geiss WB, Sargent BJ, Swenson BD, Usyatinsky A, Wyle MJ, Boucher RC, Smith RT, Zamurs A, Johnson MR. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem. 2006 Jul 13;49(14):4098-115. doi: 10.1021/jm051134w. PMID: 16821771.